Memantine Augmentation in Obsessive-Compulsive Disorder

Not Recruiting

Trial ID: NCT00264238


The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Official Title

An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder

Stanford Investigator(s)

John Barry, MD
John Barry, MD

Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology - Adult) and, by courtesy, of Neurology

Elias Aboujaoude, MD, MA

Clinical Professor, Psychiatry and Behavioral Sciences


Inclusion Criteria:

   - at least 18 years of age

   - suffering from OCD

   - Y-BOCS score of 18 or greater

   - taking a therapeutic dose of an anti-OCD medication specified in the protocol

Exclusion Criteria:

   - diagnosed with a mental disorder other than OCD

   - taking tiagabine or pregabalin

   - having had a previous trial of memantine

   - receiving therapy for OCD

   - substance abuse in the last 6 months

   - personality disorders sufficiently severe to interfere with study participation


drug: Memantine

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Nona Gamel